The introduction of our first bispecific candidate for inflammatory diseases, CDX-622, builds on our leadership in mast cell biology,” said Anthony Marucci, Co-founder, President and Chief Executive ...
For those of us diagnosed with a rare disease, the Orphan Drug Act of 1982 has been a lighthouse of hope for a perilous journey. The ODA recognized the lethal ...